Transgenic mouse models of dopamine deficiency

Annals of Neurology

Volumn 54, Issue SUPPL. 6, 2003, Pages

  Chen, Linan ^b   Zhuang, Xiaoxi ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; ADRENALIN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CARRIER PROTEIN; CATECHOL METHYLTRANSFERASE; CYCLIC AMP; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE TRANSPORTER; EXCITATORY AMINO ACID; GLUTAMIC ACID; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LEVODOPA; MESSENGER RNA; MONOAMINE; NEUROTRANSMITTER; NITRIC OXIDE; NORADRENALIN; SEROTONIN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; TETRAHYDROBIOPTERIN; TYROSINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; DISEASE MODEL; DOPAMINE DEFICIENCY; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE INSERTION; GENE INTERACTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC DISORDER; GENETIC VARIABILITY; HEREDITY; HUMAN; MENTAL DISEASE; MOUSE; MUTATIONAL ANALYSIS; NEUROCHEMISTRY; NEUROLOGIC DISEASE; NEUROPSYCHIATRY; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; HUMANS; MENTAL DISORDERS; MICE; MICE, TRANSGENIC; NERVOUS SYSTEM DISEASES; RECEPTORS, DOPAMINE; SIGNAL TRANSDUCTION;

EID: 0042367423     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10655     Document Type: Conference Paper

References (105)

1. Price DL, Tanzi RE, Borchelt DR, Sisodia SS. Alzheimer's disease: genetic studies and transgenic models. Annu Rev Genet 1998;32:461-493
2. Tecott LH, Wehner JM. Mouse molecular genetic technologies: promise for psychiatric research. Arch Gen Psychiatry 2001;58:995-1004.
3. Gingrich JA, Hen R. Dissecting the role of the serotonin system in neuropsychiatric disorders using knockout mice. Psychopharmacology (Berlin) 2001;155:1-10.
4. Ludecke B, Knappskog PM, Clayton PT, et al. Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum Mol Genet 1996;5:1023-1028.
5. Swaans RJ, Rondot P, Renier WO, et al. Four novel mutations in the tyrosine hydroxylase gene in patients with infantile parkinsonism. Ann Hum Genet 2000;64:25-31.
6. Dionisi-Vici C, Hoffmann GF, Leuzzi V, et al. Tyrosine hydroxylase deficiency with severe clinical course: clinical and biochemical investigations and optimization of therapy. J Pediatr. 2000;136:560-562.
7. Janssen RJ, Wevers RA, Haussler M, et al. A branch site mutation leading to aberrant splicing of the human tyrosine hydroxylase gene in a child with a severe extrapyramidal movement disorder. Ann Hum Genet 2000;64:375-382.
8. Zhou QY, Quaife CJ, Palmiter RD. Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature 1995;374: 640-643.
9. Zhou QY, Palmiter RD. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 1995;83:1197-1209.
10. Szczypka MS, Rainey MA, Kim DS, et al. Feeding behavior in dopamine-deficient mice. Proc Natl Acad Sci USA 1999;96: 12138-12143.
11. Zigmond MJ, Stricker EM. Deficits in feeding behavior after intraventricular injection of 6-hydroxydopamine in rats. Science 1972;177:1211-1214.
12. Segawa M. Hereditary progressive dystonia with marked diurnal fluctuation. Brain Dev 2000;22(suppl 1):S65-S80.
13. Ichinose H, Suzuki T, Inagaki H, et al. Molecular genetics of dopa-responsive dystonia. Biol Chem 1999;380:1355-1364.
14. Nishiyama N, Yukishita S, Hagiwata H, et al. Gene mutation in hereditary progressive dystonia with marked diurnal fluctuation (HPD), strictly defined dopa-responsive dystonia. Brain Dev 2000;22 Suppl 1:S102-S106.
15. Bandmann O, Valente EM, Holmans P, et al. Dopa-responsive dystonia: a clinical and molecular genetic study. Ann Neurol 1998;44:649-656.
16. Montanez CS, McDonald JD. Linkage analysis of the hph-1 mutation and the GTP cyclohydrolase I structural gene. Mol Genet Metab 1999;68:91-92.
17. Gutlich M, Ziegler I, Witter K, et al. Molecular characterization of HPH-1: a mouse mutant deficient in GTP cyclohydrolase I activity. Biochem Biophys Res Commun 1994;203: 1675-1681.
18. Hyland K, Gunasekera RS, Engle T, Arnold LA. Tetrahydrobiopterin and biogenic amine metabolism in the hph-1 mouse. J Neurochem 1996;67:752-759.
19. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
20. Baas H. Dyskinesia in Parkinson's disease: pathophysiology and clinical risk factors. J Neurol 2000;247(suppl 4):IV/2-IV/6.
21. Chase TN, Mouradian MM, Engber TM. Motor response complications and the function of striatal efferent systems. Neurology 1993;43:S23-S27.
22. Hyland K, Clayton PT. Aromatic amino acid decarboxylase deficiency in twins. J Inherit Metab Dis 1990;13: 301-304.
23. Maller A, Hyland K, Milstien S, et al. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a second family. J Child Neurol 1997;12: 349-354.
24. Swoboda KJ, Hyland K, Goldstein DS, et al. Clinical and therapeutic observations in aromatic L-amino acid decarboxylase deficiency. Neurology 1999;53:1205-1211.
25. Kunugi H, Ishida S, Akahane A, Nanko S. Exon/intron boundaries, novel polymorphisms, and association analysis with schizophrenia of the human synaptic vesicle monoamine transporter (SVMT) gene. Mol Psychiatry 2001;6: 456-460.
26. Fon EA, Pothos EN, Sun BC, et al. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 1997;19:1271-1283.
27. Wang YM, Gainetdinov RR, Fumagalli F, et al. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 1997;19:1285-1296.
28. Takahashi N, Miner LL, Sora I, et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 1997;94: 9938-9943.
29. Cook EH Jr., Stein MA, Krasowski MD, et al. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 1995;56:993-998.
30. Gill M, Daly G, Heron S, et al. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol Psychiatry 1997;2: 311-313.
31. Waldman ID, Rowe DC, Abramowitz A, et al. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am J Hum Genet 1998; 63:1767-1776.
32. Fuke S, Suo S, Takahashi N, et al. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J 2001;1:152-156
33. Dougherty DD, Bonab AA, Spencer TJ, et al. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 1999;354:2132-2133.
34. Giros B, Jaber M, Jones SR, et al. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996;379:606-612.
35. Bosse R, Fumagalli F, Jaber M, et al. Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter. Neuron 1997;19:127-138.
36. Jones SR, Gainetdinov RR, Jaber M, et al. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA 1998;95:4029-4034.
37. Zhuang X, Oosting RS, Jones SR, et al. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc Natl Acad Sci USA 2001;98:1982-1987.
38. Castellanos FX, Elia J, Kruesi MJ, et al. Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder. Psychiatry Res. 1994;52:305-316.
39. Castellanos FX, Elia J, Kruesi MJ, et al. Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder. Neuropsychopharmacology 1996;14:125-137.
40. Gainetdinov RR, Wetsel WC, Jones SR, et al. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999;283:397-401.
41. Knutson B, Wolkowitz OM, Cole SW, et al. Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry 1998;155:373-379.
42. Lavine R. Psychopharmacological treatment of aggression and violence in the substance using population. J Psychoactive Drugs 1997;29:321-329.
43. Brunner HG, Nelen M, Breakefield XO, et al. Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science 1993;262:578-580.
44. Collins FA, Murphy DL, Reiss AL, et al. Clinical, biochemical, and neuropsychiatric evaluation of a patient with a contiguous gene syndrome due to a microdeletion Xp11.3 including the Norrie disease locus and monoamine oxidase (MAOA and MAOB) genes. Am J Med Genet 1992;42:127-134.
45. Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 1998;103: 273-279.
46. Cases O, Seif I, Grimsby J, et al. Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science 1995;268:1763-1766.
47. Karayiorgou M, Morris MA, Morrow B, et al. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc Natl Acad Sci USA 1995;92:7612-7616.
48. Liu H, Heath SC, Sobin C, et al. Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proc Natl Acad Sci USA 2002;99:3717-3722.
49. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001;98: 6917-6922.
50. Tiihonen J, Hallikainen T, Lachman H, et al. Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism. Mol Psychiatry 1999;4:286-289.
51. Gogos JA, Morgan M, Luine V, et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 1998;95:9991-9996.
52. Liu Q, Sobell JL, Heston LL, Sommer SS. Screening the dopamine D1 receptor gene in 131 schizophrenics and eight alcoholics: identification of polymorphisms but lack of functionally significant sequence changes. Am J Med Genet 1995; 60:165-171.
53. Ohara K, Ulpian C, Seeman P, et al. Schizophrenia: dopamine D1 receptor sequence is normal, but has DNA polymorphisms. Neuropsychopharmacology 1993;8:131-135.
54. Thompson M, Comings DE, Feder L, et al. Mutation screening of the dopamine D1 receptor gene in Tourette's syndrome and alcohol dependent patients. Am J Med Genet 1998;81: 241-244.
55. Xu M, Moratalla R, Gold LH, et al. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 1994; 79:729-742.
56. Drago J, Gerfen CR, Westphal H, Steiner H. D1 dopamine receptor-deficient mouse: cocaine-induced regulation of immediate-early gene and substance P expression in the striatum. Neuroscience 1996;74:813-823.
57. El-Ghundi M, Fletcher PJ, Drago J, et al. Spatial learning deficit in dopamine D(1) receptor knockout mice. Eur J Pharmacol 1999;383:95-106.
58. Belluscio L, Gold GH, Nemes A, Axel R. Mice deficient in G(olf) are anosmic. Neuron 1998;20:69-81.
59. Zhuang X, Belluscio L, Hen R. G(olf)alpha mediates dopamine D1 receptor signaling. J Neurosci 2000;20:RC91.
60. Corvol JC, Studler JM, Schonn JS, et al. Galpha(olf) is necessary for coupling D1 and A2a receptors to adenylyl cyclase in the striatum. J Neurochem 2001;76:1585-1588.
61. Blum K, Noble EP, Sheridan PJ, et al. Allelic association of human dopamine D2 receptor gene in alcoholism. J Am Med Assoc 1990;263:2055-2060.
62. Blum K, Braverman ER, Holder JM, et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs 2000;32(suppl i-iv):1-112.
63. Pohjalainen T, Rinne JO, Nagren K, et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998; 3:256-260.
64. Arinami T, Itokawa M, Enguchi H, et al. Association of dopamine D2 receptor molecular variant with schizophrenia. Lancet 1994;343:703-704.
65. Tataranni PA, Baier L, Jenkinson C, et al. A Ser311Cys mutation in the human dopamine receptor D2 gene is associated with reduced energy expenditure. Diabetes 2001;50:901-904.
66. Morimoto K, Miyatake R, Nakamura M, et al. Delusional disorder: molecular genetic evidence for dopamine psychosis. Neuropsychopharmacology 2002;26:794-801.
67. Klein C, Brin MF, Kramer P et al. Association of a missense change in the D2 dopamine receptor with myoclonus dystonia. Proc Natl Acad Sci USA 1999;96:5173-5176.
68. Baik JH, Picetti R, Saiardi A, et al. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 1995;377:424-428.
69. Jung MY, Skryabin BV, Arai M, et al. Potentiation of the D2 mutant motor phenotype in mice lacking dopamine D2 and D3 receptors. Neuroscience 1999;91:911-924
70. Kelly MA, Rubinstein M, Phillips TJ, et al. Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J Neurosci 1998;18:3470-3479.
71. Phillips TJ, Brown KJ, Burkhart-Kasch S, et al. Alcohol preference and sensitivity are markedly reduced in mice lacking dopamine D2 receptors. Nat Neurosci 1998;1:610-615.
72. Maldonado R, Saiardi A, Valverde O, et al. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature 1997;388:586-589.
73. Joyce JN. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther 2001;90:231-259.
74. Crocq MA, Mant R, Asherson P, et al. Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J Med Genet 1992;29:858-860.
75. Shaikh S, Collier DA, Sham PC, et al. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Genet 1996;97: 714-719.
76. Sivagnanasundaram S, Morris AG, Gaitonde EJ et al. A cluster of single nucleotide polymorphisms in the 5'-leader of the human dopamine D3 receptor gene (DRD3) and its relationship to schizophrenia. Neurosci Lett 2000;279:13-16.
77. Xu M, Koeltzow TE, Santiago GT, et al. Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron 1997;19:837-848.
78. Accili D, Fishburn CS, Drago J, et al. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 1996;93:1945-1949.
79. Nothen MM, Cichon S, Hemmer S, et al. Human dopamine D4 receptor gene: frequent occurrence of a null allele and observation of homozygosity. Hum Mol Genet 1994;3:2207-2212.
80. LaHoste GJ, Swanson JM, Wigal SB, et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry 1996;1:121-124.
81. Swanson J, Oosterlaan J, Murias M, et al. Attention deficit/hyperactivity disorder children with a 7-repeat allele of the dopamine receptor D4 gene have extreme behavior but normal performance on critical neuropsychological tests of attention. Proc Natl Acad Sci USA 2000;97:4754-4759.
82. Benjamin J, Li L, Patterson C, et al. Population and familial association between the D4 dopamine receptor gene and measures of novelty seeking. Nat Genet 1996;12:81-84.
83. Ebstein RP, Novick O, Umansky R, et al. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of novelty seeking. Nat Genet. 1996; 12:78-80.
84. Muglia P, Jain U, Macciardi F, Kennedy JL. Adult attention deficit hyperactivity disorder and the dopamine D4 receptor gene. Am J Med Genet 2000;96:273-277.
85. Rubinstein M, Phillips TJ, Bunzow JR, et al. Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell 1997;90:991-1001.
86. Dulawa SC, Grandy DK, Low MJ, et al. Dopamine D4 receptor knockout mice exhibit reduced exploration of novel stimuli. J Neurosci 1999;19:9550-9556.
87. Sobell JL, Lind TJ, Sigurdson DC, et al. The D5 dopamine receptor gene in schizophrenia: identification of a nonsense change and multiple missense changes but lack of association with disease. Hum Mol Genet 1995;4:507-514.
88. Wang J, Liu ZL, Chen B. Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson's disease. Neurosci Lett 2001; 308:21-24.
89. Sommer SS, Sobell JL, Heston LL. A common exonic polymorphism in the human D5 dopamine receptor gene. Hum Genet 1993;92:633-634.
90. Sherrington R, Mankoo B, Attwood J, et al. Cloning of the human dopamine D5 receptor gene and identification of a highly polymorphic microsatellite for the DRD5 locus that shows tight linkage to the chromosome 4p reference marker RAF1P1. Genomics 1993;18:423-425.
91. Misbahuddin A, Placzek MR, Chaudhuri KR, et al. A polymorphism in the dopamine receptor DRD5 is associated with blepharospasm. Neurology 2002;58:124-126.
92. Placzek MR, Misbahuddin A, Chaudhuri KR, et al. Cervical dystonia is associated with a polymorphism in the dopamine (D5) receptor gene. J Neurol Neurosurg Psychiatry 2001;71: 262-264.
93. Hollon TR, Bek MJ, Lachowicz JE, et al. Mice lacking D5 dopamine receptors have increased sympathetic tone and are hypertensive. J Neurosci 2002;22:10801-10810.
94. Holmes A, Hollon TR, Gleason TC, et al. Behavioral characterization of dopamine D5 receptor null mutant mice. Behav Neurosci 2001;115:1129-1144.
95. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
96. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18:106-108.
97. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-608.
98. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998;395:451-452.
99. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003;299:256-259.
100. Le WD, Xu P, Jankovic J, et al. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 2003;33: 85-89.
101. Meyers EN, Lewandoski M, Martin GR. An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination. Nat Genet 1998;18:136-141.
102. Crawley JN. What's Wrong With My mouse? Behavioral Phenotyping of Transgenic and Knockout Mice. New York: Wiley-Liss, 2000.
103. Goldman-Rakic PS. The cortical dopamine system: role in memory and cognition. Adv Pharmacol 1998;42:707-711.
104. Ho MY, Mobini S, Chiang TJ, et al. Theory and method in the quantitative analysis of "impulsive choice" behaviour: implications for psychopharmacology. Psychopharmacology (Berlin) 1999;146:362-372.
105. Oosterlaan J, Logan GD, Sergeant JA. Response inhibition in AD/HD, CD, comorbid AD/HD + CD, anxious, and control children: a meta-analysis of studies with the stop task. J Child Psychol Psychiatry 1998;39:411-425.